Retatrutide cuts A1c and weight in phase 3 type 2 diabetes trial
Lilly's triple GIP/GLP-1/glucagon agonist showed significant reductions on both glycemic and weight endpoints in its late-stage diabetes program.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 3 03:00 ETSource: Pharmacy Times
The wire
- 01A phase 3 trial of retatrutide reported significant hemoglobin A1c reduction alongside weight loss in patients with type 2 diabetes.
- 02Retatrutide is the most-watched next-generation incretin behind tirzepatide, and diabetes data shape how broadly it may eventually be used.
- 03Full effect sizes, comparator arms and tolerability details determine how it stacks up against approved agents; the trial is sponsor-run.
From the source
Read at pharmacytimes.comRetatrutide Delivers Significant Hemoglobin A1C Reduction, Weight Loss in Phase 3 Type 2 Diabetes Trial